Literature DB >> 15569065

Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry.

B Zavizion1, D Serebryanik, J Chapman, B Alford, A Purmal.   

Abstract

BACKGROUND AND OBJECTIVES: The risk of transfusion-transmitted bacterial infections as a result of the presence of bacteria in blood is one of the major concerns in transfusion medicine. The purpose of this study was to investigate whether bacteria inoculated into red blood cell concentrates can be inactivated by the INACTINE PEN110 pathogen-reduction process. Four bacterial species were chosen for the study: anaerobic Gram-positive Clostridium perfringens and Propionibacterium acnes, known to be transfusion-transmitted; and two Gram-negative species, Acinetobacter johnsonii and Acinetobacter lwoffii, recently reported to be a common cause of transfusion-associated infections in Europe.
MATERIALS AND METHODS: Identical units of leucoreduced red cell concentrates were inoculated with A. johnsonii, A. lwoffii, C. perfringens, or P. acnes. The 4 degrees C control units were put on storage immediately after receiving the spike. The test units were subjected to PEN110 treatment and then stored. The bacterial titre in all units was monitored during a 6-week storage period.
RESULTS: The PEN110 inactivation of all tested bacterial strains was time- and titre-dependent. For A. johnsonii and A. lwoffii, no viable bacteria were detected in the units spiked with up to 10(4) colony-forming units (CFU)/ml and treated with PEN110. For red cell units spiked with 10(4)-10(5) CFU/ml of C. perfringens and P. acnes, no viable bacteria were detected in the units treated with PEN110. In control units, there was a gradual decrease in A. johnsonii, A. lwoffii and C. perfringens titres during cold storage, while P. acnes titres remained stable.
CONCLUSIONS: The PEN110 pathogen-reduction process was demonstrated to inactivate high titres of A. johnsonii, A. lwoffii, C. perfringens and P. acnes in red cell concentrates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569065     DOI: 10.1111/j.1423-0410.2004.00556.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  8 in total

1.  French Haemovigilance Data on Platelet Transfusion.

Authors:  Béatrice Willaert; Mai-Phuong Vo Mai; Cyril Caldani
Journal:  Transfus Med Hemother       Date:  2008-03-19       Impact factor: 3.747

2.  Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria.

Authors:  Thomas H Müller; Thomas Montag; Axel W Seltsam
Journal:  Transfus Med Hemother       Date:  2011-07-08       Impact factor: 3.747

3.  Malaria.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Malaria.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Bernd Jansen; Horst Klamm; Wolf-Dieter Ludwig; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Hannelore Willkommen; Karl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2008-03-17       Impact factor: 3.747

Review 5.  Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Authors:  Susan Yonemura; Suzann Doane; Shawn Keil; Raymond Goodrich; Heather Pidcoke; Marcia Cardoso
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

Review 6.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 7.  Transfusion-transmitted infections.

Authors:  Florian Bihl; Damiano Castelli; Francesco Marincola; Roger Y Dodd; Christian Brander
Journal:  J Transl Med       Date:  2007-06-06       Impact factor: 5.531

Review 8.  [Malaria. Statements of the Blood Work Group of the Federal Health Ministry].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-02       Impact factor: 1.513

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.